Discovery of IDO1 Inhibitors: From Bench to Bedside https://t.co/5u7eoaQmGA pic.twitter.com/s1wbHKvr9m
— Tom Silver (@TomSilver39) December 29, 2017
REVIEW Chemistry, mechanism and clinical status of antisense oligonucleotides and duplex RNAs #RNAi #siRNA #antisense #oligonucleotide $ALNY $IONS $ARWR $DRNA $RGLS $GERN $AKCAhttps://t.co/ienDpFManf pic.twitter.com/X5U5xZGHTl
— Oligotherapeutics (@OTSociety) January 8, 2018
Excellent review on gene therapy in @sciencemagazine this weekhttps://t.co/cjvVYIqbCS$ONCE $BLUE $AVXS $BMRN $QURE $JUNO$BOLD $RGNX $RARE $ADVM $SRPT $SLDB pic.twitter.com/L09V7u23rc
— Andy Biotech (@AndyBiotech) January 12, 2018
In patients with #alzheimers, solanezumab at a dose of 400 mg every 4 weeks does not affect cognitive decline. Full study: https://t.co/vtshP8jD97 pic.twitter.com/eFLbk0kEoo
— NEJM (@NEJM) January 24, 2018
Gene Therapy stocks getting rocked by James Wilson's new paper raising severe tox concerns$AVXS -7%$SLDB -7%$BOLD -5%$SGMO -4%$ABEO -4%$QURE -4%$RGNX -4%https://t.co/VKer7kLCuv
— Andy Biotech (@AndyBiotech) January 30, 2018
h/t @Sport234a
5-HT2C Receptor Structures Reveal the Structural Basis of GPCR Polypharmacology https://t.co/5F2x7G3DCM
— Marta Filizola (@martafilizola) February 2, 2018
Trajectories of Injectable Cancer Drug Costs After Launch in the United States@drdgoldstein in @JCO_ASCO
— Anirban Maitra (@Aiims1742) February 2, 2018
"Regardless of competition or supplemental indications, there is a steady increase in costs"
This issue will never get old or irrelevant. https://t.co/Dp34InZ4r9 pic.twitter.com/MkCz16yxMn
The more the data comes out on coffee, the better it looks :-) ☕️
— Eric Topol (@EricTopol) February 6, 2018
Biggest review yet (w/ caveats articulated) https://t.co/MDQF4VQao3 @AnnualReviews @HarvardChanSPH @NNEdPro pic.twitter.com/F4fmXPHjU8
The kinetic roots of CRISPR-Cas targeting https://t.co/cobDpOKWd9
— Cell Reports (@CellReports) February 9, 2018
RSS Feed
